IBRX•benzinga•
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Summary
ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga